Tags

Type your tag names separated by a space and hit enter

Effect of improving glycemic control on low-density lipoprotein particle size in type 2 diabetes.
Metabolism. 2003 Dec; 52(12):1576-8.M

Abstract

The current study sought to assess the effect of improving glycemic control in type 2 diabetes on the components of diabetic dyslipidemia, especially low-density lipoprotein (LDL) size. A total of 33 type 2 diabetic patients (48.5% women, age 59.6 +/- 11.1 years, body mass index [BMI] 28.9 +/- 4.9, diabetes duration 6 [0 to 40] years, 40.7% on insulin) were seen at the hospital because of poor glycemic control (hemoglobin A(1c) [HbA(1c)] 10.33% +/- 1.89%). Triglyceride, LDL-cholesterol (LDLc, Friedewald/ ultracentrifugation), high-density lipoprotein HDL-cholesterol (HDLc, direct method), apolipoproteins AI (apoAI) and B (apoB) (immunoturbidimetry), and LDL size (gradient gel electrophoresis) were measured at baseline and after improvement in glycemic control (decrease >/= 1 percentage point in HbA(1c) and final HbA(1c) </= 8%). Improvement in glycemic control (HbA(1c) 7.01% +/- 0.63%, P <.0005 v baseline) after a follow-up of 3.5 (range, 1 to 13) months resulted in a significant reduction in LDLc (3.34 +/- 1.02 v 3.62 +/- 1.15 mmol/L, P <.05) and apoB (1.07 +/- 0.25 v 1.17 +/- 0.29 g/L, P <.01) and an increase in HDLc (1.21 +/- 0.32 v 1.13 +/- 0.34 mmol/L, P <.05) and apoAI (1.36 +/- 0.24 v 1.27 +/- 0.24 mmol/L, P < 0.01) in the whole group, and an increase in LDL particle size (25.61 +/- 0.53 v 25.10 +/- 0.31 nm, P <.005) in the 14 patients showing LDL phenotype B at baseline. No significant changes were seen in body weight or BMI. We conclude that improvement of glycemic control in type 2 diabetes improves most of the components of diabetic dyslipidemia, including a shift towards larger LDL particles in subjects with phenotype B.

Authors+Show Affiliations

Wägner AM
Department of Endocrinology, Hospital Sant Pau, Universitat Autònoma de Barcelona, Spain.
Jorba O
No affiliation info available
Rigla M
No affiliation info available
Bonet R
No affiliation info available
de Leiva A
No affiliation info available
Ordóñez-Llanos J
No affiliation info available
Pérez A
No affiliation info available

MeSH

AgedBlood GlucoseCholesterolDiabetes Mellitus, Type 2FemaleGlycated HemoglobinHumansLipoproteins, LDLMaleMiddle AgedParticle SizePhenotypeTriglycerides

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

14669158

Citation

Wägner, Ana María, et al. "Effect of Improving Glycemic Control On Low-density Lipoprotein Particle Size in Type 2 Diabetes." Metabolism: Clinical and Experimental, vol. 52, no. 12, 2003, pp. 1576-8.
Wägner AM, Jorba O, Rigla M, et al. Effect of improving glycemic control on low-density lipoprotein particle size in type 2 diabetes. Metabolism. 2003;52(12):1576-8.
Wägner, A. M., Jorba, O., Rigla, M., Bonet, R., de Leiva, A., Ordóñez-Llanos, J., & Pérez, A. (2003). Effect of improving glycemic control on low-density lipoprotein particle size in type 2 diabetes. Metabolism: Clinical and Experimental, 52(12), 1576-8.
Wägner AM, et al. Effect of Improving Glycemic Control On Low-density Lipoprotein Particle Size in Type 2 Diabetes. Metabolism. 2003;52(12):1576-8. PubMed PMID: 14669158.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of improving glycemic control on low-density lipoprotein particle size in type 2 diabetes. AU - Wägner,Ana María, AU - Jorba,Oscar, AU - Rigla,Mercedes, AU - Bonet,Rosa, AU - de Leiva,Alberto, AU - Ordóñez-Llanos,Jordi, AU - Pérez,Antonio, PY - 2003/12/12/pubmed PY - 2004/2/10/medline PY - 2003/12/12/entrez SP - 1576 EP - 8 JF - Metabolism: clinical and experimental JO - Metabolism VL - 52 IS - 12 N2 - The current study sought to assess the effect of improving glycemic control in type 2 diabetes on the components of diabetic dyslipidemia, especially low-density lipoprotein (LDL) size. A total of 33 type 2 diabetic patients (48.5% women, age 59.6 +/- 11.1 years, body mass index [BMI] 28.9 +/- 4.9, diabetes duration 6 [0 to 40] years, 40.7% on insulin) were seen at the hospital because of poor glycemic control (hemoglobin A(1c) [HbA(1c)] 10.33% +/- 1.89%). Triglyceride, LDL-cholesterol (LDLc, Friedewald/ ultracentrifugation), high-density lipoprotein HDL-cholesterol (HDLc, direct method), apolipoproteins AI (apoAI) and B (apoB) (immunoturbidimetry), and LDL size (gradient gel electrophoresis) were measured at baseline and after improvement in glycemic control (decrease >/= 1 percentage point in HbA(1c) and final HbA(1c) </= 8%). Improvement in glycemic control (HbA(1c) 7.01% +/- 0.63%, P <.0005 v baseline) after a follow-up of 3.5 (range, 1 to 13) months resulted in a significant reduction in LDLc (3.34 +/- 1.02 v 3.62 +/- 1.15 mmol/L, P <.05) and apoB (1.07 +/- 0.25 v 1.17 +/- 0.29 g/L, P <.01) and an increase in HDLc (1.21 +/- 0.32 v 1.13 +/- 0.34 mmol/L, P <.05) and apoAI (1.36 +/- 0.24 v 1.27 +/- 0.24 mmol/L, P < 0.01) in the whole group, and an increase in LDL particle size (25.61 +/- 0.53 v 25.10 +/- 0.31 nm, P <.005) in the 14 patients showing LDL phenotype B at baseline. No significant changes were seen in body weight or BMI. We conclude that improvement of glycemic control in type 2 diabetes improves most of the components of diabetic dyslipidemia, including a shift towards larger LDL particles in subjects with phenotype B. SN - 0026-0495 UR - https://www.unboundmedicine.com/medline/citation/14669158/Effect_of_improving_glycemic_control_on_low_density_lipoprotein_particle_size_in_type_2_diabetes_ DB - PRIME DP - Unbound Medicine ER -